Mark Bookbinder

Bristol-Myers Squibb

H指数:12

被引数:804

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models (vol 67, pg 1262, 2024)

PROTACs靶向BRM（SMARCA2）可在体内实现对BRG1（SMARCA4）的选择性降解，并在BRG1突变异种移植肿瘤模型中表现出活性（vol 67, pg 1262, 2024）

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2025-05-210

PRE

Berlin, Michael; Cantley, Jennifer; Bookbinder, Mark; Bortolon, Elizabeth; Broccatelli, Fabio; Cadelina, Greg; Chan, Emily W.; Chen, Huifen; Chen, Xin; Cheng, Yunxing; Cheung, Tommy K.; Crew, Andrew P.; Davenport, Kim; Dinicola, Dean; Dong, Hanqing; Gordon, Debbie; Hamman, Brian D.; Harbin, Alicia; Haskell, Roy; He, Mingtao; Hole, Alison J.; Januario, Thomas; Kerry, Philip S.; Koenig, Stefan G.; Li, Limei; Merchant, Mark; Perez-Dorado, Inmaculada; Pizzano, Jennifer; Quinn, Connor; Rose, Christopher M.; Rousseau, Emma; Snyder, Lawrence B.; Soto, Leofal; Staben, Leanna R.; Sun, Hongming; Tian, Qingping; Wang, Gan; Wang, Jing; Wang, Weifeng; Ye, Crystal S.; Ye, Xiaofen; Zhang, Penghong; Zhou, Yuhui; Yauch, Robert; Dragovich, Peter S.

PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-01-057

PRE

Berlin, Michael; Cantley, Jennifer; Bookbinder, Mark; Bortolon, Elizabeth; Broccatelli, Fabio; Cadelina, Greg; Chan, Emily W.; Chen, Huifen; Chen, Xin; Cheng, Yunxing; Cheung, Tommy K.; Davenport, Kim; DiNicola, Dean; Gordon, Debbie; Hamman, Brian D.; Harbin, Alicia; Haskell, Roy; He, Mingtao; Hole, Alison J.; Januario, Thomas; Kerry, Philip S.; Koenig, Stefan G.; Li, Limei; Merchant, Mark; Perez-Dorado, Inmaculada; Pizzano, Jennifer; Quinn, Connor; Rose, Christopher M.; Rousseau, Emma; Soto, Leofal; Staben, Leanna R.; Sun, Hongming; Tian, Qingping; Wang, Jing; Wang, Weifeng; Ye, Crystal S.; Ye, Xiaofen; Zhang, Penghong; Zhou, Yuhui; Yauch, Robert; Dragovich, Peter S.

KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models

MOLECULAR CANCER RESEARCH

IF4.7

2023-05-012

PRE

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies

MOLECULAR THERAPY-NUCLEIC ACIDS

IF0

2022-09-0112

OAAI

Easton, Amy; Jensen, Marianne L.; Wang, Congwei; Hagedorn, Peter H.; Li, Yuwen; Weed, Michael; Meredith, Jere E.; Guss, Valerie; Jones, Kelli; Gill, Martin; Krause, Carol; Brown, Jeffrey M.; Hunihan, Lisa; Natale, Joanne; Fernandes, Alda; Lu, Yifeng; Polino, Joe; Bookbinder, Mark; Cadelina, Greg; Benitex, Yulia; Sane, Ramola; Morrison, John; Drexler, Dieter; Mercer, Stephen E.; Bon, Charlotte; Pandya, Nikhil J.; Jagasia, Ravi; Yang, Tai-Hsien Ou; Distler, Tania; Grueninger, Fiona; Meldgaard, Michael; Terrigno, Marco; Macor, John E.; Albright, Charles F.; Loy, James; Hoeg, Anja M.; Olson, Richard E.; Cacace, Angela M.

Selective, chemically-induced degradation of BRM (SMARCA2) enables in vivo efficacy in BRG1 (SMARCA4)-deficient xenograft tumor models

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Berlin, Michael; Cantley, Jennifer; Wang, Jing; Bookbinder, Mark; Cadelina, Gregory; Chan, Emily; Chen, Huifen; Chen, Xin; Davenport, Kim; Fernando, Tharu; Gordon, Debbie; Hamman, Brian; Haskell, Roy; Ishchenko, Alexey; Kirkpatrick, Donald S.; Maher, Jonathan; Merchant, Mark; Moffat, John; Morgan, Alicia; Nguyen, An; Pizzano, Jennifer; Quinn, Connor; Rose, Christopher M.; Rousseau, Emma; Sethuraman, Vijay; Staben, Leanna; Wilson, Catherine; Ye, Xiaofen; Broccatelli, Fabio; Yauch, Robert; Dragovich, Peter S.

ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer

CANCER RESEARCH

IF16.6

2019-02-15114

PRE

ARV-110: An androgen receptor PROTAC degrader for prostate cancer

CANCER RESEARCH

IF16.6

2018-07-0149

PRE

Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning

PLOS ONE

IF2.6

2017-12-1910

OAAI

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorders

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2017-12-0115

OAAI

Bristow, Linda J.; Gulia, Jyoti; Weed, Michael R.; Srikumar, Bettadapura N.; Li, Yu-Wen; Graef, John D.; Naidu, Pattipati S.; Sanmathi, Charulatha; Aher, Jayant; Bastia, Tanmaya; Paschapur, Mahesh; Kalidindi, Narasimharaju; Kumar, Kuchibhotla Vijaya; Molski, Thaddeus; Pieschl, Rick; Fernandes, Alda; Brown, Jeffrey M.; Sivarao, Digavalli V.; Newberry, Kimberly; Bookbinder, Mark; Polino, Joseph; Keavy, Deborah; Newton, Amy; Shields, Eric; Simmermacher, Jean; Kempson, James; Li, Jianqing; Zhang, Huiping; Mathur, Arvind; Kallem, Raja Reddy; Sinha, Meenakshee; Ramarao, Manjunath; Vikramadithyan, Reeba K.; Thangathirupathy, Srinivasan; Warrier, Jayakumar; Islam, Imadul; Bronson, Joanne J.; Olson, Richard E.; Macor, John E.; Albright, Charlie F.; King, Dalton; Thompson, Lorin A.; Marcin, Lawrence R.; Sinz, Michael

An oral Androgen Receptor PROTAC degrader for prostate cancer

CANCER RESEARCH

IF16.6

2017-07-011

PRE

Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains

NEUROPSYCHOPHARMACOLOGY

IF7.1

2015-06-2419

OAAI

Mark Bookbinder

个人简介

教育背景

工作经历

荣誉奖项

研究方向